MedPlus Health Services Limited has disclosed to stock exchanges that its subsidiary company has received a regulatory action from Karnataka's drug control authorities. The company filed the disclosure on December 10, 2025, in compliance with SEBI listing regulations.

Regulatory Action Details

Optival Health Solutions Private Limited, a subsidiary of MedPlus Health Services, received a suspension order for its drug license from the Assistant Director, Drugs Control Administration, Hubli Circle-Hubli, Karnataka. The order was received on December 9, 2025.

Legal Framework and Compliance

The suspension order was issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company has disclosed this information pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.

Financial Impact

The company has quantified the potential financial impact of this regulatory action:

Disclosure and Transparency

MedPlus Health Services has ensured proper disclosure of this regulatory development across multiple platforms. The information has been made available on the company's official website at www.medplusindia.com , as well as on the websites of both stock exchanges - BSE Limited ( www.bseindia.com ) and National Stock Exchange of India Limited ( www.nseindia.com ). The disclosure was signed by Manoj Kumar Srivastava, Company Secretary and Compliance Officer, demonstrating the company's commitment to regulatory compliance and transparency with stakeholders.

Medplus Health Services Limited has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received multiple suspension orders for drug licenses at various stores, impacting operations in Maharashtra and Andhra Pradesh.

Latest Suspension

Optival Health Solutions Private Limited has received a suspension order for a drug license at its store in Maharashtra. The suspension, issued under the Drugs and Cosmetics Act, is for a period of 25 days. This latest action could result in a potential revenue loss of Rs 5.87 lacs for the healthcare company.

Previous Suspensions

Maharashtra

1. A store in Shanti Nagar, Nagpur received a 21-day suspension order on November 1, under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The potential revenue loss from this suspension was estimated at Rs 4.34 lacs.

2. Earlier suspensions were reported in Nagpur and Amravati, for which the company received stay orders from the appropriate authorities.

Andhra Pradesh

On October 31, a store in Devi Chowk, Rajamahendravaram, East Godavari District, received a seven-day suspension order. The potential revenue loss from this suspension was estimated at Rs 1.75 lacs.

Regulatory Challenges

These suspensions highlight the regulatory challenges faced by pharmaceutical retail chains in India. While the individual financial impacts may not be significant for MedPlus's overall operations, the frequency of these incidents raises questions about compliance across the company's network of stores.

Company's Response

Medplus Health Services Limited has been prompt in disclosing these regulatory actions to the stock exchanges, in compliance with SEBI regulations. The company has stated that it will make this information available on its website and on the websites of BSE Limited and National Stock Exchange of India Ltd.

Outlook

As the pharmaceutical retail sector continues to grow and evolve in India, companies like MedPlus may need to navigate complex regulatory environments while maintaining their business operations. Investors and stakeholders will likely be watching closely to see how MedPlus addresses these regulatory challenges and ensures compliance across its network of stores.

While these suspensions may have short-term impacts on the company's operations in specific locations, the long-term implications will depend on how effectively MedPlus can resolve these issues and prevent future occurrences.